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Abstract
Background: Atrial fibrillation (AF) is known to be associated with several pathophysiological mechanisms
including endothelial dysfunction of the heart and arterial vessels. Recent evidence suggests that new oral
anticoagulant (NOAC) treatment may improve endothelial function and the inflammatory process involved in
atherosclerosis in AF patients. This study is designed to determine the efficacy of NOAC therapy in the prevention
of endothelial dysfunction and the progression of atherosclerosis of AF subjects.
Method/design: AF patients with a CHA2DS2-VASc score >2 and no previous history of overt coronary disease,
severe peripheral arterial disease (PAD) or major stroke will be registered and randomly assigned either to the
NOAC group (dabigatran or rivaroxaban) or the warfarin group in this prospective, randomized, 2-year follow-up
study. Reactive hyperemia peripheral arterial tonometry (RH-PAT) measurements reflecting endothelial function will
be conducted using the Endo-PAT2000 device. Left and right carotid intima-media thickness (IMT) will be measured
at baseline, 12 months, and 24 months. The primary endpoint is defined as change in Reactive Hyperemia Index
(RHI) at 12 months. Secondary endpoints included changes in the right and left maximum IMT of the common
carotid artery (CCA) and internal carotid artery (ICA), the mean IMT of the CCA and ICA at 24 months, and 24-
month cardiovascular events including cardiac death, stroke, acute myocardial infarction (AMI), overall cause of
death, withdrawal of drug, or bleeding events.
Discussion: This is the first study to evaluate the efficacy of NOAC therapy for the prevention of endothelial
dysfunction and progression of atherosclerosis in AF subjects. These findings are expected to expand the
knowledge of NOAC pleotropic action in AF patients.
Trial registration: ClinicalTrials.gov: NCT02544932, registered on 7 September 2015.
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Background
Factor Xa and thrombin are well-known components of
the coagulation cascade and other biological and patho-
physiological processes that are known targets for effective
anticoagulation treatment [1]. Therefore, the properties of
oral, direct inhibitors of factor Xa (e.g., rivaroxaban) and
thrombin (e.g., dabigatran) have been examined for
hemostasis and thromboembolism management.
Accumulating evidence suggests that factor Xa and
thrombin are important modulators of other cellular sig-
naling mechanisms through the activation of protease-
activated receptor (PAR)-mediated signaling. Cross-talk
between coagulation and inflammatory pathways via
thrombin- or factor Xa-mediated PAR activation on the
arterial vessel wall and heart, and the resulting contribu-
tion to atherosclerosis and atrial fibrillation (AF), have
been well-documented [2]. The endothelium, platelets,
pro-inflammatory cytokines and chemokines, and several
serine proteases (e.g., tissue factor (TF), factor Xa, throm-
bin), via the activation of PARs, are major points in for the
promotion of inflammation and leukocyte migration,
which results in the initiation of atherosclerosis [1–4].
Preclinical studies have provided evidence for the ef-
fects of direct Xa or thrombin inhibition beyond antic-
oagulation, including anti-inflammatory and protective
activities in atherosclerotic plaque development [5–8].
Evidence has demonstrated that direct thrombin inhib-
ition impairs the formation and size of atherosclerotic
plaques in addition to preventing the progression of
endothelial injury-associated stenosis in an apolipopro-
tein E-deficient mouse model [5, 6]. Also, factor Xa in-
hibition was shown to ensure the reduction of restenosis
after balloon angioplasty of atherosclerotic femoral arter-
ies in rabbits [7].
However, questions remain regarding the treatment
concentration and adverse effects of these drugs. Fur-
thermore, there is little evidence of similar effects in pa-
tients with AF. Therefore, this study will evaluate the
protective effects of NOAC with reactive hyperemia per-
ipheral arterial tonometry (RH-PAT) measurements
made using the Endo-PAT2000 device, reflecting endo-
thelial function and intima-media thickness (IMT) of the
common carotid artery (CCA), which is used as a surro-
gate endpoint of atherosclerosis. In this study, we plan
to analyze the occurrence of cardiovascular events in AF
patients who are at high risk of these.
Method/design
Study subjects and hypothesis
Rivaroxaban and dabigatran have demonstrated potential
for the management of thromboembolic disorders such
as AF or deep vein thrombosis with or without pulmonary
thromboembolism [9, 10]. We therefore plan to initiate a
prospective, randomized, 2-year follow-up study to clarify
the efficacy of rivaroxaban and dabigatran in affecting
change of endothelial function and progression of athero-
sclerosis in AF patients. The working hypothesis of this
trial is that rivaroxaban and dabigatran are superior to
standard vitamin K (vitK)-antagonists in the prevention of
endothelial dysfunction, assessed by peripheral arterial
tone (PAT) ratio at 12 months, and the progression of
CCA-IMTat 12-month and 24-month follow-up.
Study design
This study is a prospective, randomized, 2-year follow-
up study to clarify the efficacy of rivaroxaban and dabi-
gatran in change of endothelial function and progression
of atherosclerosis in AF patients. The study algorithm is
shown in Fig. 1. After enrollment, subjects will be ran-
domly assigned to the dabigatran group (110 mg or
150 mg twice/day; group 1) or the rivaroxaban group
(20 mg/day; group 2) or the warfarin group (controlled
by international normalized ratio (INR) of 2–3; group 3).
After participation in the study procedure, clinical
follow-up will occur at 1, 3, 12, and 24 months. Follow-
up will be conducted via telephone interviews or office
visits. Any adverse reactions will be assessed. This study
is an investigator-initiated clinical trial with grant sup-
port from the Ministry of Health, Welfare, and Family
Affairs of the Republic of Korea. The authors are solely
responsible for the design, conduct, analysis, and manu-
script preparation for this study. The 2-year duration of
the study period will have a registration period from
September 2015 to February 2016, with complete study
duration from September 2015 to April 2018.
Study population
Patients aged between 40 to 85 years will be enrolled in
the study if they have been diagnosed with AF and have
a CHA2DS2-VASc score above 2 points (Table 1). The
following exclusion criteria have been set: severe periph-
eral arterial disease (PAD) (greater than a Fontaine IIb
category), grade-4 or higher cerebral infarction on the
modified Rankin Scale, and proven coronary artery dis-
ease based on coronary angiogram. In addition, patients
with a range of concomitant comorbidities including se-
vere hepatic or renal dysfunction, uncontrolled congest-
ive heart failure, uncontrolled hypertension or diabetes
mellitus, hematological disorders, or those with allergy
or hypersensitivity to the investigational drugs, pregnant
or lactating women, or women wishing to become preg-
nant, will be excluded. Written informed consent will be
obtained from all patients, and the Ethics Review Board
of Kyung Hee University Hospital will review the study.
Randomization and allocation concealment
Randomization will be performed using a computer-
generated random number list with a permuted block
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design at a 1:1:1 ratio. Adequate allocation blinding will
be ensured by the following procedure. After obtaining
participant consent, allocation information will be sent
to the main investigator at Kyung Hee University hos-
pital by telephone, and allocations will not be known by
the participants or enrolling investigators.
Outcome measures
The primary endpoint is defined as change in the
Reactive Hyperemia Index (RHI) at 12 months. Secondary
endpoints included changes in the right and left max-
imum IMT of the CCA and internal carotid artery (ICA),
mean IMT of the CCA and ICA at 24 months, and 24-
month cardiovascular events including cardiac death,
stroke, acute myocardial infarction (AMI), overall cause of
death, withdrawal of drug, or bleeding events.
Procedures
Measurement of PAT ratio will be performed with the
standard technique and device [11–14]. Endo-PAT mea-
surements will be performed at baseline and at 12 months
after randomization. The RH-PAT 2000 device (Itamar
Medical, Caesarea, Israel) will be used for digital RH-
PAT to evaluate endothelial function as previously de-
scribed. The RH-PAT Index (RHI) reflects the extent of
reactive hyperemia and is calculated as the ratio of the
average amplitude of PAT signal over 1 min starting
1.5 min after cuff deflation (control arm, A; occluded arm,
C) divided by the average amplitude of PAT signal at the
2.5-min time period before cuff inflation (baseline)
(control arm, B; occluded arm, D). Thus:
RHI ¼ C=Dð Þ= A=Bð Þ  baseline correction:
Impaired endothelial function is defined as a log RHI
less than 0.6, and favorable endothelial function is de-
fined as a log RHI more than or equal to 0.6.
Measurement of CCA-IMT will be performed with the
standard technique and device [12, 15]. Imaging studies
of the left and right carotid arteries will be performed by
expert sonographers who are well-trained in the use of
10-MHz linear vascular probes (Vivid 7, GE Vingmed
Ultrasound, Horten, Norway). Measurements will be
performed at baseline, and at 12 months and 24 months
after randomization. To avoid interobserver variability,
Fig. 1 PREFER-AF trial flow diagram. Participants will receive new oral anticoagulant (NOAC) or vitamin K (vitK)-antagonist treatment according to
the assigned sequence; then, endothelial function and clinical events will be assessed
Table 1 Enrollment criteria
Inclusion criteria
1. AF (CHA2DS2-VASc score >2 points)
2. Aged between 40 and 85 years
Exclusion criteria
1. Aged below 40 or over 85 years
2. History of myocardial infarction
3. Proven coronary artery disease by coronary angiogram
4. Cerebrovascular disorders rated as grade 4 or greater on the modified
Rankin Scale
5. Severe peripheral arterial disease rated as Fontaine IIb or over
6. Uncontrolled hypertension (180/110 mmHg) or diabetes (glycated
hemoglobin: HbA1C >10.0 %)
7. Severe hepatic dysfunction (aspartate transaminase (AST)/alanine
transaminase (ALT) >100 mg/dL)
8. Renal dysfunction (serum creatinine ≥2.0 mg/dL)
9. Uncontrolled congestive heart failure
10. Severe hematological abnormalities
11. Drug allergies or history of hypersensitivity to the investigational
drugs
12. Pregnant or lactating women, or women who wish to become
pregnant
Kim et al. Trials  (2016) 17:422 Page 3 of 5
the same investigator will examine each participant with
the same equipment throughout all the visits. The IMT
will be measured as the distance between two parallel
echogenic lines corresponding to the blood-intima and
media-adventitia interface on the posterior wall of the
artery. Three IMT determinations will be performed at
the site of the thickest point with a maximum CCA-
IMT and two adjacent points (1 cm upstream and 1 cm
downstream from this site). These three determinations
will be averaged (mean CCA-IMT). The CCA is defined
as the segment extending from 10 to 20 mm proximal to
the tip of the common carotid bifurcation site. The ICA
is defined as the segment 10 mm distal to the tip of the
common carotid bifurcation site, and the bifurcation is
defined as the segment between the CCA and the ICA.
Carotid IMT will be measured using dedicated software
(Intimascope, Media Cross Co., Tokyo, Japan) by an
examiner blinded to all clinical information.
Blood samples will be obtained from subjects in the
fasting state. The von Willebrand factor, interleukin
(IL)-10, and adiponectin endothelial cell markers, the
IL-6, tumor necrosis factor alpha (TNF-α), and high-
sensitivity C-reactive protein (hs-CRP) inflammatory
markers, the vascular adhesion molecule and ICAM-1
adhesion molecules, and the CD-40 ligand, P-selectin,
and cathepsin-K platelet activation markers will be mea-
sured using standard methods.
Sample size measure and statistics
This study is a prospective, pilot study for a proof of
concept trial. In a previous studies, the RHI was
1.63 ± 0.28 in patients with permanent/persistent AF
[13, 14]. We assume that NOAC will improve RHI
values by an 8 % difference with no significant differ-
ence between the two different NOACs. The ex-
pected difference in RHI was driven from clinical
significances and previous medical treatments in
other study population [16–18]. To detect a statisti-
cally significant difference with a power of 80 % with
a two-sided α-level of 0.05, a sample of 165 patients
(55 patients for each group) will be required. Assum-
ing dropout rates would be 20 %, the total sample
size will be set at 198 subjects.
Statistical analyses will be carried out using the SPSS
Statistics for Windows ver. 17.0 software package (SPSS
Inc., Chicago, IL, USA). A two-sided p < 0.05 is consid-
ered significant. Continuous variables, presented as
means ± standard deviations, will be evaluated for nor-
mal distribution and compared using the Student t test
or analysis of variance test accordingly. The continuous
parameters with a skewed distribution will be logarith-
mically transformed and categorical variables, presented
as frequencies and percentages, will be compared using
the chi-square test or Fisher’s exact test when appropriate.
Repeated measures parameters over time between the
groups will be determined by repeated measure analysis of
variance with an autoregressive model or analysis of co-
variance adjusting for baseline values. The clinical event
rates will be assessed using the Kaplan-Meier method and
the log-rank test will be used to compare survival between
the two groups and the Cox proportional hazards model
will be used for multivariate analysis (forward stepwise) to
investigate which of the parameters identified using uni-
variate analysis are significantly associated with clinical
events.
Discussion
The aim of this study is to determine the efficacy of
NOAC therapy in the prevention of endothelial dysfunc-
tion and progression of atherosclerosis in AF subjects.
Recent evidence suggests that AF adversely affects endo-
thelial function [11, 13, 14]. Further, conversion of AF to
sinus rhythm results in improved flow-mediated vaso-
dilatation (FMD) in patients with persistent AF [13, 14].
It is not known whether the vitK antagonists are effect-
ive in affecting endothelial function and atherosclerotic
progression in AF patients. Preclinical evidence shows
that NOACs are effective in reducing inflammatory cyto-
kines and atherosclerotic cascades [5–8]; however, clin-
ical data are lacking. We believe that the therapeutic
effects resulting from aspirin or warfarin and NOACs,
which have different mechanisms of action, have not
been sufficiently investigated in AF patients. The results
of this study are expected to broaden our understanding
of NOAC mechanisms in humans and lead to the de-
velopment of appropriate drug therapies for patients
with AF and atherosclerosis. This is a very important
objective because the incidence of AF and its com-
mon complications are rising at a staggering rate in
many countries.
One of the study limitations is that the primary out-
come in this study is not a hard endpoint for clinical
outcome but a surrogate marker for endothelial dysfunc-
tion. Therefore, further study for clinical outcome of
vascular events comparing NOACs and warfarin should
follow after this trial. Furthermore, this study is not
double-blind trial. To minimize the bias, the technician
performing examination and analysis will be blind to the
allocation of patients.
Trial status
This study is ongoing. We are currently recruiting and
enrolling subjects at the Kyung Hee University Medical
Center.
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